Q4 2021 Results

NEW INDICATIONS Participants Company overview Pharmaceuticals Financial performance Oncology Innovation: Pipeline overview Novartis submission schedule New Molecular Entities: Lead and supplementary indications LEAD INDICATIONS 2022 2023 ligelizumab¹ Lead iptacopan LNP023 QGE031 CSU PNH sabatolimab² Lead MBG453 HR-MDS ensovibep Lead SKO136 COVID19 tislelizumab VDT482 1L Nasopharyngeal Carcinoma tislelizumab VDT482 NSCLC Financial review Conclusion Appendix Innovation: Clinical trials 2024 2025 ≥2026 Lead JDQ443 JDQ443 Lead icenticaftor Lead 177 Lu-NeoB Lead ganaplacide Lead QBW251 AAA603 KAF156 LXE408 Visceral leishmaniasis Lead 2/3L NSCLC (mono) COPD Multiple Solid Tumors Malaria uncomplicated remibrutinib Lead NIS793 Lead branaplam Lead iscalimab Lead LXH254 Lead LMI070 CFZ533 Solid tumors (combos) LOU064 1L Pancreatic cancer Huntington's disease CSU Sjögren's syndrome UNR844 Presbyopia Lead pelacarsen TQJ230 CVRR-Lp(a) Lead cipargamin Lead ianalumab Lead MIJ821 Lead KAE609 VAY736 Acute depression Malaria severe Sjögren's syndrome YTB323 Lead CPK850 Lead libvatrep Lead TNO155 Lead Solid tumors RP SAF312 2L Diffuse large B-cell lymphoma COSP CSJ117 Lead LNA043 Lead tropifexor&licogliflozi Lead Asthma Knee osteoarthritis LJN452 NASH (combos) gevokizumab Lead VPM087 1st line CRC / 1st line RCC LCM 177Lu-PSMA-617 LCM 177Lu-PSMA-617 LCM asciminib LCM asciminib LCM ianalumab LCM AAA617 ABL001 ABL001 VAY736 AAA617 MHSPC CML 1L CML, 2L, pediatrics AIH Pre-taxane LCM iptacopan LCM sabatolimab LCM iptacopan LCM cipargamin LCM iptacopan LCM LNP023 MBG453 C3G Unfit AML LNP023 aHUS KAE609 Malaria uncomplicated LNP023 iMN iptacopan LCM tislelizumab LCM ligelizumab LCM JDQ443 LCM LNP023 VDT482 QGE031 JDQ443 IgAN 1L Small Cell Lung Cancer Food allergy NSCLC (Combo) tislelizumab LCM tislelizumab LCM VDT482 VDT482 1L Gastric Cancer 1L Bladder Urothelial Cell Carcinoma ligelizumab QGE031 CINDU LCM tislelizumab LCM VDT482 1L ESCC remibrutinib LOU064 Multiple sclerosis LCM tislelizumab LCM VDT482 Localized ESCC tislelizumab VDT482 LCM 1L Hepatocellular Carcinoma 1. Ph3 data in evaluation. 2. Filing opportunity in 2022/2023, based on PFS and/or OS outcomes from a dual approach based on parallel Phase 2 and Phase 3 trials. 64 Investor Relations | Q4 2021 Results iscalimab LCM CFZ533 Liver Tx remibrutinib LOU064 Sjögren's syndrome LCM U NOVARTIS | Reimagining Medicine

View entire presentation